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Drug–membrane interactionPlasmodium, the parasite which causes malaria in humans multiplies in the liver and then infects circulating
erythrocytes. Thus, the role of the erythrocyte cell membrane in antimalarial drug activity and resistance has
key importance. The effects of the antiplasmodial N6-(4-methoxybenzyl)quinazoline-2,4,6-triamine (M4), and
its inclusion complex (M4/HPβCD) with 2-hydroxypropyl-β-cyclodextrin (HPβCD) on human erythrocytes
and on cell membrane molecular models are herein reported. This work evidences that M4/HPβCD interacts
with red cells as follows: a) in scanning electron microscopy (SEM) studies on human erythrocytes induced
shape changes at a 10 μMconcentration; b) in isolatedunsealed human erythrocytemembranes (IUM) a concen-
tration as low as 1 μM induced sharp DPH ﬂuorescence anisotropy decrease whereas increasing concentrations
produced a monotonically decrease of DPH ﬂuorescence lifetime at 37 °C; c) X-ray diffraction studies showed
that 200 μM induced a complete structural perturbation of dimyristoylphosphatidylcholine (DMPC) bilayers
whereas no signiﬁcant effects were detected in dimyristoylphosphatidylethanolamine (DMPE) bilayers, classes
of lipids present in the outer and inner monolayers of the human erythrocyte membrane, respectively; d) ﬂuo-
rescence spectroscopy data showed that increasing concentrations of the complex interacted with the deep hy-
drophobic core of DMPC large unilamellar vesicles (LUV) at 18 °C. All these experiments are consistent with the
insertion ofM4/HPβCD in the outermonolayer of the human erythrocytemembrane; thus, it can be considered a
promising and novel antimalarial agent.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Malaria is a disease caused by parasites of the genus Plasmodium
spp. and it is transmitted via the bites of infected female Anopheles
mosquitoes. Plasmodium falciparum and Plasmodium vivax are the
prevalent species but the former is the most lethal. In the human
body, parasitesmultiply in the liver, and then infect circulating erythro-
cytes where a cyclic asexual replication takes place bringing the cycles
of fever and chills characteristic of malaria. If untreated, this infection
can progress into severe illness often leading to death [1]. Malaria isIUM, isolated unsealed erythro-
rge unilamellar vesicles; DMPC,
hatidylethanolamine; r, ﬂuores-
enyl-1,3,5-hexatriene; laurdan,
ydrofolate reductase; M4, N6-
odextrins; HPβCD, 2-hydroxy-
+56 41 2245974.
l rights reserved.endemic of tropical and subtropical regions, and approximately half of
the world population lives at risk of this parasitic disease. With about
225 million of infected people and nearly 800,000 deaths in 2009, ma-
laria is still considered one of themost severe diseases in the developing
world [2]. Cure and prevention of malaria depend principally on drug
therapy. Although several drugs have been commercialized, their use
is now severely limited by the emergence and widespread of drug resis-
tance. Furthermore, several reports indicate that these parasites have de-
veloped at least partial resistance to almost every antimalarial regimen
introduced to date, including the former ﬁrst-line drugs chloroquine
and sulfadoxine–pyrimethamine [3–7]. Because of resistance, treatment
failure is frequent, resulting in an increase of mortality and complicating
the control of the infection. Therefore, there is an urgent need to gain in-
formation about the basicmechanisms throughwhich antimalarial drugs
act and resistance is generated in order not only to identify new targets
and develop new drugs with novel mechanisms of action, but also to
take advantage of the mode of action of available drugs and make better
use of them [6,7]. An extensively studied target has been the inhibition of
folate metabolism. The antifolate drugs used for malaria therapy are
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(PfDHPS), and pyrimethamine, which inhibits dihydrofolate reductase
(PfDHFR) activity of the bifunctional dihydrofolate reductase/thymidy-
late synthase enzyme, essential systems for parasitic DNA synthesis.
The drug combination sulfadoxine–pyrimethamine (Fansidar)was intro-
duced in the 70s after the emergence of parasite resistance to chloro-
quine. It used to be a highly effective, affordable, and well-tolerated
drug combination until the emergence of resistant parasites [7]. Numer-
ous efforts have been directed toward the discovery of new PfDHFR
inhibitors, being quinazoline derivatives themost promising compounds
[8–12].
Pharmacological activity of a drug frequently involves an initial in-
teraction with cell membranes, even if they are not the ﬁnal targets.
Given the important role of the erythrocytes host cell membrane on
drug resistance,more investigation about antimalarial drug–membrane
interaction is needed. In this context, it was decided to study N6-(4-
methoxybenzyl)quinazoline-2,4,6-triamine, synthesized in the 70s as
a promising PfDHFR inhibitor. Its synthesis and antiplasmodial activity
were initially described, but the investigation was apparently aban-
doned [8]. This quinazoline derivative, named in this work as M4
(Fig. 1),was used to investigate its interactionwith human erythrocytes
and cell membrane molecular models in order to have an understand-
ing, at both cellular and molecular levels about the relation between
the compound and the erythrocyte membrane. When M4 was synthe-
sized according to the described procedure [8], it showed poor aqueous
solubility but high solubility in dimethylsulfoxide (DMSO), an organic
solvent widely employed in pre-formulations of new compounds in bi-
ological trials. However, investigations have shown that DMSO does
exert a direct effect on the major characteristics of model membranes
[13], which could potentially hinder this work. To overcome these
drawbacks, increasing the aqueous solubility of M4 was of importance
and this was achieved through the formation of an inclusion complex
with a modiﬁed cyclodextrin. Cyclodextrins (CDs) are cyclic oligomers
formed by glucopyranose molecules bound through 1–4 bonds, and
aremost commonly composed by 6 (α-CD), 7 (β-CD) or 8 (δ-CD) glucose
units. CDs are able to form inclusion complexes with different classes of
molecules, modifying their physical, chemical and biological properties
[14]. Among CDs, 2-hydroxypropyl-β-cyclodextrin (HPβCD) appears to
be especially useful given its low toxicity, complexation potential and
great water solubility [15,16]. Thus, the inclusion complex of M4 with
HPβCD (M4/HPβCD) was prepared in order to study the interaction of
the quinazoline derivative withmembrane phospholipids circumventing
the use of DMSO. The characterization of the complex consisted on phase
solubility studies, nuclear magnetic resonance and mass spectrometry
experiments. Afterwards, the interaction of M4/HPβCD with human red
blood cells andmolecular models of the erythrocyte membrane was car-
ried out. The inﬂuence of M4/HPβCD on morphology of intact human
erythrocytes was examined by scanning electron microscopy (SEM),
while isolated unsealed human erythrocyte membranes (IUM) were
studied by ﬂuorescence spectroscopy. Molecular models consisted of bi-
layers of dimyristoylphosphatidylcholine (DMPC) and dimyristoylpho-
sphatidylethanolamine (DMPE), representative of phospholipid classes
located in the outer and inner monolayers of the human erythrocyte
membrane, respectively [17,18]. The capacity of M4/HPβCD to perturb
the bilayer structures of DMPC and DMPE was assessed by X-ray diffrac-
tionwhile DMPC large unilamellar vesicles (LUV)were additionally stud-
ied by ﬂuorescence spectroscopy.Fig. 1. Structure formula of N6(4-methoxybenzyl)quinazoline-2,4,6-triamine (M4).2. Materials and methods
2.1. X-ray structure determination of M4
M4 single crystals were mounted at 123 K on a Bruker SMART dif-
fractometer equipped with an Apex CCD area detector. Frames were
collected by omega scans, and integrated with the Bruker SAINT soft-
ware package using the appropriate unit cell [19]; the structure was
solved using the SHELXS-97 program [20] and reﬁned by full-matrix
least-squares on F2 with SHELXL-97 [21]. Weighted R-factors, Rw,
and all goodness of ﬁt indicators, S, were based on F2. The observed
criterion of (F2>2σF2) was used only for calculating the R-factors.
All non-hydrogen atoms were reﬁned with anisotropic thermal pa-
rameters in the ﬁnal cycles of reﬁnement. Hydrogen atoms were
placed in idealized positions. Isotropic thermal parameters of the hydro-
gen atoms were assigned the values of Uiso=1.2 times the thermal pa-
rameters of the parent non-hydrogen atom. Data: Mol. wt.=608.71,
triclinic, space group P-1, a=10.3555(15) Å, b=11.4769(16) Å,
c=13.8216(19) Å, α=92.356(3)º, β=111.367(3)°, γ=102.190(3)°,
V=1482.7(4) Å3. T=123(2) K, Z=2, Dcalc=1.363 g cm−3,
μ=0.092 mm−1, 5492 Reﬂections collected, 5492 independent
(Rint=0.0393), ﬁnal R1 [I≥2σ(I)]=0.0439, wR(F2)=0.1006, S=1.052.
2.2. Preparation of the inclusion complex
The inclusion complex was obtained by mixing M4 and HPβCD in
water at 1:1 molar ratio. The mixture was stirred at 25 °C for 7 days
protected from light to prevent degradation. After this period, the sol-
vent was evaporated to dryness at 45 °C under vacuum (Vacuubrand
CVC2II). The resulting solid was collected, pulverized and sieved
(200 μm sieve).
2.3. Determination of intrinsic solubility
The intrinsic solubility of M4 and the solubility proﬁle of M4/
HPβCD were determined by the shake-ﬂask method [22]. Brieﬂy, an
aliquot of 5 ml of phosphate buffer solution, pH 7.4, was added to a
glass vial containing 5 mg of M4 or its mass equivalent as a complex
in order to have an excess of solid. The vials were stirred during
48 h at 25 °C followed by a sedimentation period of 18 h for phase
separation. The amount of dissolved compound was analyzed by UV
spectrophotometry at 290 nm (Genesys10uv, Thermo). Three inde-
pendent experiments were carried out.
2.4. Phase solubility diagram
In order to determine the effect of HPβCD on the solubility of M4,
phase solubility studies were performed according to the method de-
scribed by Higuchi and Connors [23]. Brieﬂy, aqueous solutions con-
taining increasing concentrations of HPβCD were prepared (0.2, 0.4,
0.6, 0.8 and 1 mM). A constant amount of M4 in ﬁve-fold molar excess
relative to the highest concentration of HPβCD solution was added to
the HPβCD solution; the resulting suspensions were stirred during 48 h
at room temperature. After this period, the suspensions were ﬁltered
through 0.2 μm membranes (Millex, Millipore) and M4 concentration
was analyzed by means of an UV spectrophotometer at 290 nm (Gene-
sys10uv, Thermo). Phase solubility diagrams were obtained by plotting
M4 solubility versus HPβCD concentration. This experiment was re-
peated three times.
2.5. NMR spectroscopy
1H and ROESY NMR spectra were obtained from a Bruker Avance
III spectrometer at 400 MHz; samples of M4 were referenced relative
to the residual protons of DMSO-d6 at δ 2.50 ppm. ROESY spectra
were acquired with a mixing time of 200 ms.
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Electrospray mass spectrometry experiments were performed
with a Bruker Daltonics Esquire 6000 spectrometer with ion trap;
data were collected from ca. 5 mM 1:1 M4/HPβCD aqueous solutions.
2.7. Scanning electron microscopy (SEM) studies of human erythrocytes
The interaction of M4/HPβCDwith human erythrocytes was studied
in vitro according to the following procedure. Five blood drops from a
non medicated human healthy donor were obtained by puncturing
the ear lobule and placed in an Eppendorf tube containing 10 μl of hep-
arin (5000 UI/ml) in 900 μl of saline solution (0.9% NaCl, pH 7.4); the
tube was mixed manually and then centrifuged (1000 rpm for
10 min); the supernatant was discarded and replaced by the same vol-
ume of saline solution; thewhole processwas repeated three times. The
sedimented erythrocytes were suspended in 900 μl of saline solution,
and 100 μl of this suspension was mixed with equal volumes of either
saline solution (control) or 100 μl of the adequate M4/HPβCD stock sa-
line solutions to obtain the ﬁnal concentrations of 10, 50, 100, 150, 200
and 250 μM (relative to M4). In vitro interactions of HPβCD (250 μM)
and free M4 (as an aqueous suspension ca. 250 μM) with red blood
cells were also evaluated. Samples were incubated at 37 °C for 1 h.
After this period samples were centrifuged at 1000 rpm for 10 min
and the supernatant was discarded. To ﬁx the erythrocytes, 500 μl of
2.5% glutaraldehyde was added to each sample followed by incubation
at 4 °C overnight. Fixed cells were washed with distilled water, and di-
rectly placed over Al glass cover stubs, air-dried at 37 °C for 30 min, and
gold-coated for 3 min at 10−1 Torr in a sputter device (Edwards S150,
Sussex, England). Resulting specimens were examined in a Jeol SEM
(JSM 6380 LB, Japan).
2.8. Fluorescence measurements of DMPC large unilamellar vesicles
(LUV) and of isolated unsealed human erythrocyte membranes (IUM)
The inﬂuence of M4/HPβCD on the physical properties of DMPC
LUV and IUM was studied by ﬂuorescence spectroscopy using DPH
(1,6-diphenyl-1,3,5-hexatriene) ﬂuorescent probe (Molecular Probes,
Invitrogen, Carlsbad, CA). DMPC large unilamellar vesicles (LUV) sus-
pended in water were prepared by extrusion of frozen and thawed
multilamellar liposome suspensions (ﬁnal lipid concentration
0.4 mM) through two stacked polycarbonate ﬁlters of 400 nm pore
size (Nucleopore, Corning Costar Corp., MA, USA) under nitrogen
pressure at 10 °C above the lipid phase transition temperature. Eryth-
rocytes were separated from heparinized venous blood samples
obtained from regular non-medicated casual donors by centrifugation
and washing procedures. IUM were prepared by lysis, according to
Dodge et al. [24]. DPHwas incorporated intoDMPC LUVand IUMsuspen-
sions by addition of adequate aliquot of 0.5 mM solution of the probe in
DMSO in order to obtain a ﬁnal concentration of 1×10−3 mM. After-
wards, the suspensions were incubated at 37 °C for 1 h. Steady state
and time-resolved ﬂuorescent measurements were performed on a K2
multifrequency phase shift and modulation spectroﬂuorometer (ISS
Inc., Champaign, IL, USA) interfaced to computers. Software from ISS
was used for data collection and analysis. The exciting light was from a
modulable ISS 375 nm Light Emitting Diode (LED) laser. M4 and M4/
HPβCDwere incorporated into LUV suspensions by addition of adequate
aliquots of a stock solution of M4 or M4/HPβCD (250 μM in a water-
DMSO 50:50 mixture) in order to get the ﬁnal concentrations used in
these experiments (1–10 μM, where the maximum of DMSO was 0.2%).
Samples were then incubated at 37 °C for ca. 15 min and measured at
twodifferent temperatures bymeansof 5 mmpath-length square quartz
cuvettes: 18 °C because the X-ray experiments were performed at this
temperature and 37 °C because that is the normal physiological temper-
ature. Sample temperature was controlled by an external bath circulator
(Cole-Parmer, Chicago, IL, USA) and monitored before and after eachmeasurement using anOmega digital thermometer (Omega Engineering
Inc., Stanford, CT, USA). Anisotropy measurements were made in the L
conﬁguration using Glan–Thompson prismpolarizers (ISS) in both excit-
ing and emitting beams. The emission was measured using a WG-420
Schott high-passﬁlter (SchottWG-420,Mainz, Germany)with negligible
ﬂuorescence. Blank subtraction was performed in all measurements
using unlabeled samples without probes. The acquired results represent
mean values and standard error of ten measurements in two indepen-
dent samples. Unpaired Student's t-test was used for statistical calcula-
tions. DPH ﬂuorescence anisotropy (r) was calculated according to the
deﬁnition: r=(I||− I⊥)/(I||+2I⊥) where I|| and I⊥ are the corresponding
vertical and horizontal emission ﬂuorescence intensities with respect to
the vertically polarized excitation light [25]. In addition, the deﬁnition
of the average anisotropy of amixture ofﬂuorophorswas used to deter-
mine the value of DPH anisotropy. In the experimental conditions there
were two species that have ﬂuorescence properties:M4 andDPHprobe.
The average anisotropy for a mixture of ﬂuorophors is given by:
r ¼∑i f iri, where fi is the fraction of intensity for each species, and ri
is the anisotropy for each component of themixture. Thus the anisotro-
py of DPH was calculated by the equation: r ¼ f DPHrDPH þ f M4rM4.
For ﬂuorescence decay determination, lifetime measurements were
performed with the polarizers oriented in the “magic angle” condition
[26]. Phase and modulation values were obtained at ten modulation fre-
quencies (5–80 MHz) as previously described [27]. Dimethyl-POPOP
(1,4-bis[2]4-Methyl-5-phenyloxazoly benzene) in ethanol (t=1.45 ns)
was used as a reference of intensity decay. Time-resolved ﬂuorescence
intensity decay data of DPHwas analyzed using a Lorentzian lifetime dis-
tribution. A ﬁxed discrete lifetime component of 0.01 ns was used to ac-
count for scattered light, which was b2% in terms of fractional intensity
contribution. The Lorentzian lifetime distribution center obtained from
the analysis is informed as DPH lifetime.
2.9. X-ray diffraction studies of phospholipid multilayers
The capacity of the M4/HPβCD complex to perturb the structures of
DMPC and DMPE multilayers was evaluated by X-ray diffraction. Syn-
thetic DMPC (lot 140PC-248, MW 677.9) and DMPE (lot 140PE-58,
MW635.9) fromAvanti (ALA, USA),were usedwithout further puriﬁca-
tion. Approximately 2 mg of each phospholipid were mixed in Eppen-
dorf tubes with 200 μl of (a) distilled water or (b) aqueous solutions
of M4/HPβCD in the range of concentrations of 1 to 250 μM (relative
to M4); free M4 was evaluated as a suspension at ca. 250 μM. The mix-
tures were incubated during 30 min at 37 °C and 60 °C with DMPC and
DMPE respectively, and centrifuged for 10 min at 2500 rpm. Samples
were then transferred to 1.5 mm diameter special glass capillaries
(Glas-Technik & Konstruktion, Berlin, Germany) and X-ray diffracted
utilizing Ni-ﬁltered Cu-Kα radiation from a Bruker Kristalloﬂex 760
(Karlsruhe, Germany) X-ray system. Specimen-to-ﬁlm distances were
8 and 14 cm, standardized by sprinkling calcite powder on the capillary
surface. Relative reﬂection intensities were obtained in anMBraun PSD-
50M linear position-sensitive detector system (Garching, Germany);
no correction factors were applied. The experiments were performed
at 18 °C±1 °C, which is below the main phase transition temperature
of both phospholipids. Higher temperatureswould have induced transi-
tions to further ﬂuid phases making the detection of structural changes
more difﬁcult. Each experimentwas performed by triplicate. X-ray data
were analyzed using the Origin software 7.0.
3. Results
3.1. X-ray crystallography
The solid-state structure of M4 was determined by single-crystal
X-ray diffraction in order to conﬁrm its identity, and also to determine
the spatial arrangement of the aromatic rings; yellow-orange plates
were grown from an approximately 1:1 water/ethanol concentrated
Table 1
Hydrogen bonding parameters (Å, °) for M4.
D\H⋯A Symmetry operation D\H H⋯A D⋯A D\H⋯A
N4B\H44⋯O1A −x, 1−y, −z 0.876 2.253 2.984 140.85
N4A\H42⋯O1B −x, 1−y, −z 0.894 2.251 2.989 139.72
N4B\H43⋯N3A 1−x, 2−y, 1−z 0.879 2.175 3.014 159.39
N4A\H41⋯N3B 1−x, 2−y, 1−z 0.899 2.125 3.019 172.77
N2B\H24⋯N1A 2−x, 2−y, 1−z 0.878 2.082 2.959 177.96
N2A\H22⋯N1B 2−x, 2−y, 1−z 0.892 2.139 3.026 172.71
O2\H26⋯N1A 2−x, 2−y, 1−z 0.877 2.142 2.985 161.18
O2\H25⋯N1B 0.878 2.158 3.002 161.24
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there are two independent molecules in the asymmetric unit with vir-
tually identical parameters, except for the non-coplanar angles between
the phenyl and quinazoline rings in eachmolecule, which correspond to
68.54 and 59.52° for molecules A and B (Fig. 2). An extended hydrogen-
bond network stabilizes the lattice, involving intermolecular N\H⋯N
base pairing, as well as N\H⋯O (methoxy) and N⋯H\O (water) inter-
actions (Table 1). The bond lengths and angles are similar to those for
related quinazoline derivatives [28,29].
3.2. Determination of intrinsic solubility
The aqueous solubility of M4 and M4/HPβCD is presented in
Table 2. According to these results, the improvement of M4 solubility
in water through the formation of an inclusion complex with HPβCD
increased 10.4 times.
3.3. Phase solubility diagram
Fig. 3 shows a solubility curve that can be classiﬁed as AL type di-
agram, which indicates that there is a linear increase in M4 solubility
with increasing concentrations of HPβCD. This result is indicative of
the formation of a soluble complex between M4 and this cyclodextrin
[23]. Because such proﬁle is characterized by a slope of less than 1, it was
assumed that the solubility increase was due to the formation of a 1:1
complex [23]. From the straight line of the phase-solubility diagram
the apparent stability constant (K1:1) was estimated according to the
equation K1:1=m/So(1−m), where m is the slope of the linear plot
and So is M4 aqueous solubility (So=0.00935 mg/ml, 0.0000316 M) de-
termined as described above. The value of K1:1 is a useful index to esti-
mate the degree of binding strength of the complex. The magnitude of
K1:1 is generally in the range 0–100,000 M−1 with 0 being the value
for a drug that is incapable of forming an inclusion complex; values
less than 100 M−1 denoteweak guest–host associations, whereas values
close to 10,000 M−1 indicate strong interactions, and 100,000 M−1
being near the upper value observed experimentally for cyclodextrin
complexes of drugs [30]. The K1:1 value for the M4/HPβCD inclusion
complex was 2765 M−1, suggesting that there is a favorable interaction
between the quinazoline derivative and the cyclodextrin.
3.4. 1H NMR spectroscopy
The inclusion mode of M4 with the cyclodextrin was examined by
NMR spectroscopy. Due to the poor solubility of M4 in water, its 1H
NMR spectrum was acquired in DMSO-d6. The aliphatic signals at δ
3.65 and 4.17 ppm were assigned to CH3O\ and \CH2NH\ protons,
with relative intensities of 3 H and 2 H, respectively. The aromatic re-
gion is characterized by the presence of two doublets corresponding
to the coupled protons in the disubstituted phenyl ring at δ 6.82
and 7.27 ppm (J=10.6 Hz). A singlet at δ 6.86 ppm overlaps with
the former doublet, giving rise to an apparent multiplet that inte-
grates to 3 H; in addition, a broad singlet at δ 7.05 ppm correspondingFig. 2. ORTEP diagram of one of the independent molecules (A) of M4 at the 50% prob-
ability level with atom labeling scheme; hydrogen atoms and a water molecule were
removed for clarity.to two protons of the quinazoline ring gives a total of 7 aromatic pro-
tons, as expected for M4. Detailed information on the inclusion of M4
within the cavity of HPβCD was obtained from 2D NMR experiments,
speciﬁcally with Rotating-frame NOE spectroscopy (ROESY). The 2D
spectrum of the M4/HPβCD system was acquired in DMSO-d6; the
ROESY contour plot reveals that the doublet corresponding to the
phenyl ring at δ 6.82 ppm has a strong intermolecular cross-peak
with H-3 on the wide side of the cavity of HPβCD at δ 3.65 ppm
(Fig. 4). This indicates that M4 forms an inclusion complex through
its 4-methoxyphenyl group with the cyclodextrin in DMSO, result
that agrees with the phase-solubility diagram in aqueous solution.
3.5. Mass spectrometry
Electrospray (ESI) mass spectrometry experiments revealed a dis-
tribution of peaks between m/z=1180 and 2000; the ones between
m/z=1215.5 and 1737.8 are associated to sodium cationized
HPβCD with varying degrees of substitution with hydroxypropyl
groups (Fig. 5). The peaks at m/z=1778.8, 1836.9 and 1895.9 corre-
spond to the inclusion complexes [M4+(6)+H]+, [M4+(7)+H]+,
and [M4+(8)+H]+, respectively; the number in parenthesis repre-
sents the number of hydroxypropyl substituents on the cyclodextrin.
These experimental data are consistent with predominant inclusion
compounds with 1:1 stoichiometry.
3.6. Scanning electron microscopy (SEM) studies of human erythrocytes
The effects of the interaction of M4 and M4/HPβCD with human
erythrocytes were evaluated in vitro by SEM. The resulting micro-
graphs (Fig. 6) show that the inclusion complex induced notorious
changes in the morphology of the red blood cells. The normal resting
shape of the human red blood cell is a ﬂattened biconcave disc shape
(discocyte) ~8 μm in diameter which can be observed in Fig. 6A, cor-
responding to the erythrocytes incubated with saline solution (control).
On the other hand, morphological analysis of the results revealed that
M4/HPβCD changed the normal shape of the red blood cells in a dose-
dependentmanner. Fig. 6B (10 μM) clearly shows that discocytes under-
went a transformation to class I echinocytes, which are erythrocytes
with crenated shapes [31]; nevertheless knizocytes (term designating
a triconcave red-cell shape) were present as well. M4/HPβCD at
100 μM gave rise to echinocytosis phenomenon with the presence of
class III echinocytes (quasi spherical body covered with roundTable 2






a SCD: M4/HPβCD complex solubility.
b SM4: M4 solubility.
















Fig. 3. Phase-solubility diagram for M4/HPβCD host–guest system at 25 °C.
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(erythrocytes with cup-like shapes) were also found (Fig. 6C). Cellular
polymorphism was produced at 250 μM, where the presence of echino-
cytes, knizocytes, stomatocytes and ellyptocytes (abnormally shaped
elongated red blood cells) was evident (Fig. 6D). The effects of the sep-
arate components were also studied. Minor cell transformation was in-
duced by HPβCD, although some stomatocytes and knizocytes were
present (Fig. 6E). In the case of free M4 (Fig. 6F) echinocytes were the
dominating shape. The quinazoline derivative also produced some
knizocytes and stomatocytes. Very few discocytes were observed.
Thus, SEM observations evidenced that M4/HPβCD affected humanM4
8ppm 7.5 7 6.5 6 5.5 5 4.5 4
Phenyl
ppm 7.5 7.0 6.5 6.0 5.5 5.0 4.5
B
A
Fig. 4. 1H NMR (A) and ROESYerythrocytes in all range of concentrations and induced predomi-
nantly the formation of echinocytes.3.7. Fluorescence measurements of DMPC large unilamellar vesicles
(LUV) and of isolated unsealed human erythrocyte membranes (IUM)
DPH, an extrinsic membrane probe, was used because of its favor-
able spectral properties for the phospholipids deep hydrophobic acyl
chain region. Lipid acyl chain packing order and water penetration
changes were obtained from steady state and time resolved ﬂuores-
cence measurements. Steady state DPH ﬂuorescence anisotropy
changes due to the interactions of free M4 and M4/HPβCD with the
deep hydrophobic core of DMPC LUV are depicted in Fig. 7. These results
show that increasing concentrations of free M4 or M4/HPβCD substan-
tially decreased the anisotropy values at 18 °C. Similarly, there was a
moderate decrease of anisotropy at 37 °C, when the lipid bilayer is in
the liquid-crystalline state. Fig. 8 shows the effect on DPH anisotropy
at 37 °C of M4 and M4/HPβCD in IUM. As it can be appreciated, a con-
centration as low as 1 μM of each compound induced sharp anisotropy
decrease where the major change occurred upon the addition of this
concentration, with subsequent slight decreases at higher concentra-
tions. Fig. 9 shows that increasing M4 and M4/HPβCD concentrations
produced a monotonically decrease of DPH lifetime in IUM at 37 °C;
however, increasing amounts of the free compound and the complex
did not show a signiﬁcant effect on the DPH lifetime in DMPC LUV at
both studied temperatures (data not show).HPβCD
H3 of HPβCD
3.5 3 2.5 2 1.5 1
4.0 3.5 3.0
spectra (B) of M4/HPβCD.
Fig. 5. Electrospray mass spectrum of M4/HPβCD aqueous solution; numbers shown in
brackets refer to the number of hydroxypropyl groups bound to cyclodextrin.
Fig. 7. Effect of M4/HPβCD and M4 on the steady state ﬂuorescence anisotropy of DPH
in DMPC LUV at 18 °C and 37 °C.
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Fig. 10A exhibits the results obtained by incubating DMPC with
water, M4/HPβCD, free M4 and HPβCD. As expected, water altered
the structure of DMPC; its bilayer repeat distance (phospholipid bi-
layer width plus the layer of water) increased from about 55 Å in itsFig. 6. Effect of M4/HPβCD, M4 and HPβCD on the morphology of human erythrocytes: (A) co
250 μM; (F) M4.crystalline form to 64.5 Å when immersed in water, and its low-
angle reﬂections (indicated as LA) were reduced to only the ﬁrst
two orders of the bilayer repeat [32]. On the other hand, only one
strong reﬂection of 4.2 Å showed up in the wide-angle region (indi-
cated as WA), which corresponds to the average distance between
fully extended acyl chains organized with rotational disorder inntrol; (B) M4/HPβCD 10 μM; (C) M4/HPβCD 100 μM; (D) M4/HPβCD 250 μM; (E) HPβCD
Fig. 8. Effect of M4/HPβCD and M4 on the steady state ﬂuorescence anisotropy of DPH
in IUM at 37 °C.
Fig. 10.Microdensitograms from X-ray diffraction patterns of: (A) DMPC and (B) DMPE
in water, aqueous solutions of M4/HPβCD, and aqueous suspension of free M4; (LA)
and (WA) correspond to low- and wide angle reﬂections, respectively.
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the Pβ′ gel phase. Fig. 10A discloses that after exposure to increasing
M4/HPβCD concentrations there was a monotonically decrease of
DMPC LA and WA reﬂection intensities, which became negligible at
250 μM. From these results it can be concluded that M4/HPβCD pro-
duced a structural perturbation of DMPCbilayers and, as a consequence,
a disruption of the in-plane structure and the bilayer stacking. On the
other hand, while HPβCD induced a slight increase of DMPC intensities,
the opposite effectwas detected in the case of freeM4. Interestingly, the
effect of M4 suspension on DMPC intensities was not as strong as that
observed when the quinazoline derivative is complexed, suggesting
that cyclodextrin is promoting the interaction of M4 with the bilayer.
Results from similar experiments with DMPE, presented in Fig. 10B,
show only two reﬂections: one of 56.4 Å corresponding to the bilayer
width, and another of 4.2 Å similar to that observed in DMPC. AdditionalFig. 9. Effect of M4/HPβCD and M4 on DPH ﬂuorescence lifetime in IUM at 37 °C.reﬂections were not detected with the used set-up. As reported else-
where, water did not signiﬁcantly affect the bilayer structure of DMPE
[32]. It is possible to observe that increasing M4/HPβCD concentrations
did not signiﬁcantly affect DMPE structure even at the maximum
assayed concentration (250 μM). Similarly, neither HPβCD nor M4 in-
duced any structural perturbation to DMPE bilayers.
4. Discussion
Although numerous efforts have been made in order to discover
novel antimalarial agents and develop novel strategies to overcome
resistance, the mode of action and mechanisms of resistance of
some of the drugs available today are not fully understood. However,
it has been reported that resistance could be related to interactions
with biological membranes, interaction with membrane proteins or
modiﬁcations in the lipid structure [33,34]. Since the pharmacological
activity of a molecule frequently involves an initial interaction of the
drug with the membrane phospholipids, even if they are not the ﬁnal
target of the drug molecule, and the important role of the erythro-
cytes host cell membrane on the drug resistance, more investigation
about antimalarial drug–membrane interaction is needed. In this
paper it is reported the interaction of M4, an antiplasmodial drug
complexed with HPβCD, with human red blood cells and molecular
models of the erythrocyte membrane. The inﬂuence of M4/HPβCD
on morphology of intact human erythrocytes was examined by SEM,
while IUMwere studied by ﬂuorescence spectroscopy. In addition, in-
teractions of M4/HPβCD with DMPC and DMPE lipid bilayers were
performed by X-ray diffraction and ﬂuorescence spectroscopy. X-ray
crystallography data conﬁrmed the identity of the quinazoline deriv-
ative. In order to increase the aqueous solubility of M4 and to avoid
the use of organic solvents which could affect the membrane molecular
models used in this work, an inclusion complex with HPβCD was pre-
pared. The complex was characterized through 1H NMR data and ESI
mass spectrometry, to determine the association type and stoichiometry
betweenM4 and HPβCD respectively; phase-solubility studies indicated
that HPβCD enhancedwater solubility of M4 through the inclusion com-
plex formation. It is well known that some external factors as well as se-
lective intercalation of foreign species into the outer or innermonolayer
of the membrane result in shape changes of the erythrocyte membrane
[35–38]. The bilayer-couple hypothesis proposes that crenated shapes
(echinocytes) are observed when some agents interact with the outer
monolayer while cup-shapes (stomatocytes) are produced when an
745Y. Rojas-Aguirre et al. / Biochimica et Biophysica Acta 1818 (2012) 738–746interaction takes place in the inner leaﬂet due to the differential expan-
sion of this membrane monolayer [35].
The results obtained when erythrocytes were incubated in the
presence of M4 suspension show that echinocytes were the predom-
inant shape, indicating that the quinazoline derivative might be inter-
calated in the outer membrane leaﬂet relative to the inner one.
Nonetheless, stomatocytes were also observed (Fig. 6F). An explana-
tion for this ﬁnding could be a time-dependent effect: it has been
reported that when a molecule initially intercalates into the outer
leaﬂet, causing echinocytosis, it can slowly migrate to the inner leaf-
let, causing a return to the discocyte structure followed by subse-
quent stomatocytosis [39]. HPβCD alone also exerted an effect on
the normal cell shape; although it cannot be considered drastic, sto-
matocytes are clearly present in Fig. 6E. Occurrence of these erythro-
cyte shapes might be partially due to the capacity of CDs to extract
cholesterol from cell membranes. β-Cyclodextrin and its derivatives
have demonstrated a great capacity to subtract cholesterol from the
biological membrane, altering the properties of the lipidic bilayer
[40–43]. In addition, it has been reported that depletion of membrane
cholesterol promotes stomatocytosis [44]. The inclusion complex M4/
HPβCD induced the formation of echinocytes predominantly. This
phenomenon can be explained either by the insertion of the inclusion
complex in the outer leaﬂet of the membrane, or by the insertion of
M4 delivered from the complex. SEM micrographs also revealed the
presence of stomatocytes, explained partially by the effect of the indi-
vidual components as explained above, or the effect of the M4/HPβCD
system.
Fluorescence experiments conﬁrmed SEM results. The observed
changes in LUV and IUM were accomplished at lower concentrations
than those in which the ﬁrst changes were evident, in both X-ray dif-
fraction and SEM, demonstrating the great sensitivity of this method.
DPH steady state ﬂuorescence anisotropy results, due to its hindered
rotational diffusion in the bilayer, indicated that M4 and M4/HPβCD
induced a monotonous decrease in the lipid acyl chain packing
order at the deep hydrophobic region of DMPC LUVs bilayer (Fig. 7).
These changes were substantial in LUV in the gel state (18 °C) and mod-
erate in the liquid crystalline state (37 °C). However, in IUM (Fig. 8), a
considerable order decrease occurred mostly upon the ﬁrst addition of
1 μM of both M4 and M4/HPβCD. The ﬂuorescence lifetime of DPH in a
given medium depends on its surrounding dielectric environment pro-
vided that no excited state reactions occur. Small alterations in the degree
of hydration have been shown to affect signiﬁcantly theﬂuorescence life-
time due to ﬂuorophor excited statewater interactions [45]. Consequent-
ly, ﬂuorescence lifetime measurements can be used to infer changes in
the water content of the ﬂuorophor environment. Increasing amounts
of the free compound and the complex did not show a signiﬁcant effect
on the DPH lifetime in DMPC LUV at both studied temperatures (data
not shown). However, there is a large effect on DPH lifetime in IUM,
with a steady decline throughout the concentration range tested
(Fig. 9). We suggest that these larger effects on IUM than on ﬂuid phase
of DMPC LUVs were due to the presence of lipid–protein interfaces in
the erythrocyte membrane. There is considerable evidence that water
penetrates into lipid bilayers, at least as far as the glycerol backbone
and also deeper between fatty acyl chain packing defects [46]. Lipid–
protein interfaces in natural membranes are places of membrane de-
fects, where water is present. It might be that these interfaces are the
main locations of both additives inside the membrane. On the other
hand, considering that the erythrocytemembrane has high protein con-
tent, lipids and proteins must be in close proximity. Thus, all DPH mol-
ecules should also be in very close proximity to lipid–protein interfaces.
In this context, free M4 and M4/HPβCD induced DPH lifetime decrease
in IUM should indicate a hydration increase in the lipid–protein
interfaces.
X-ray diffraction performed on bilayers made up of DMPC and
DMPE, classes of the major phospholipids present in the outer and
inner sides of the erythrocyte membrane agree with those observedin SEM and ﬂuorescence experiments. In fact, they respectively
showed that M4/HPβCD disordered the polar head and acyl chain re-
gions of DMPC whereas DMPE bilayers were not affected by M4/
HPβCD even at the highest assayed concentration. DMPC and DMPE
differ only in their terminal amino groups, these being +N(CH3)3 in
DMPC and +NH3 in DMPE. Moreover, both molecular conformations
are very similar in their dry crystalline phases with the hydrocarbon
chains mostly parallel and extended, and the polar head groups
lying perpendicularly to them [32]. However, the gradual hydration
of DMPC results in water ﬁlling the highly polar interbilayer spaces
with the concomitant increase of their width. This phenomenon
allowed the incorporation of M4/HPβCD into DMPC bilayers with
the resulting disruption of its structure. On the other hand, DMPE
molecules pack tighter than those of DMPC due to their smaller
polar groups andhigher effective charge, resulting in a very stable bilayer
system that is not signiﬁcantly affected bywater. The strong electrostatic
interaction and hydrogen bond system also prevented M4/HPβCD from
interacting with DMPE and perturbing its structure.
5. Conclusions
PfDHFR inhibitors such as quinazoline derivatives act in the intra-
erythrocytic stage of the parasite. To reach this site, drugs have ﬁrst to
interact with erythrocyte membrane. Thus, understanding drug–
membrane interaction at molecular level is essential. Present experi-
mental outcomes demonstrated that M4 as an HPβCD inclusion com-
plex interacted with the human erythrocyte lipid bilayer. All results
indicated that M4/HPβCD interacted mainly with the outer leaﬂet of
the membrane, where it perturbs the lipid acyl chains ordering and
augmented the hydration of the lipid–protein interfaces in the mem-
brane interior where this compound is able to penetrate. Additionally,
the results indicate that cyclodextrin facilitated the interaction of M4
with the membrane, a strong reason to consider M4/HPβCD a prom-
ising formulation for the treatment of malaria. These results are very
valuable because they seem to indicate that alternative modes of in-
teraction of the drug might be operating, starting at the erythrocyte
membrane prior to reaching the intracellular target. This in turn
could provide key information to tackle the wider issue of drug
resistance.
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